Fabrice Balavoine - Quantum Genomics Director of Research & Development
ALQGC Stock | EUR 0.12 0.01 7.69% |
Director
Mr. Fabrice Balavoine serves as Director of Research Development at Quantum Genomics SA. He is cofounder of Galactis Pharma and served previously as Vice President Chemistry of Sepal Pharma, Drug Discovery Director of Cerep and its subsidiary Anceris specialized in oncology. He also led several projects at the Ecole Nationale Superieure de Chimie de Paris, at Harvard Medical School and at the Commissariat a lEnergie Atomique in the areas of labeled molecules, structural biology, nanobiotechnology, and chemical genetics
Professional Marks | MBA |
Phone | 33 1 85 34 77 70 |
Web | https://www.quantum-genomics.com |
Quantum Genomics Management Efficiency
The company has return on total asset (ROA) of (0.4751) % which means that it has lost $0.4751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2274) %, meaning that it generated substantial loss on money invested by shareholders. Quantum Genomics' management efficiency ratios could be used to measure how well Quantum Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 1 records | DIRECTOR Age | ||
LaureHelene Mercier | Innate Pharma | 39 |
Management Performance
Return On Equity | -1.23 | |||
Return On Asset | -0.48 |
Quantum Genomics Leadership Team
Elected by the shareholders, the Quantum Genomics' board of directors comprises two types of representatives: Quantum Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quantum. The board's role is to monitor Quantum Genomics' management team and ensure that shareholders' interests are well served. Quantum Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quantum Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Stephane Cohen, Chief Officer | ||
Fabrice Balavoine, Director of Research & Development | ||
Sarah MerlenBoulenger, Head Affairs | ||
Olivier Madonna, Medical Director | ||
Lionel Segard, Chairman of the Board and CEO | ||
Bruno Besse, Chief Officer | ||
Christian Bechon, Director | ||
Marc Karako, CFO, Director | ||
Maurice Salama, Director | ||
Benot Gueugnon, VP Director | ||
JeanPhilippe Milon, Vice President - Operations |
Quantum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quantum Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.23 | |||
Return On Asset | -0.48 | |||
Operating Margin | (5.48) % | |||
Current Valuation | (11.33 M) | |||
Shares Outstanding | 34.53 M | |||
Shares Owned By Insiders | 9.18 % | |||
Shares Owned By Institutions | 3.69 % | |||
Price To Earning | (5.10) X | |||
Price To Book | 0.32 X | |||
Price To Sales | 1.07 X |
Pair Trading with Quantum Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Quantum Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quantum Genomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Quantum Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Quantum Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Quantum Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Quantum Genomics SA to buy it.
The correlation of Quantum Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Quantum Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Quantum Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Quantum Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Quantum Genomics SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Quantum Genomics information on this page should be used as a complementary analysis to other Quantum Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Quantum Stock analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |